Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
The New England Journal of Medicine|November 15, 2013
Case of the Massachusetts General Hospital: Case 35-2013: a 77-year-old man with confusion and malaiseJeffrey A Barnes, Jeremy S Abramson, James A Scott, et al.
AJR. American Journal of Roentgenology|May 23, 2015
Projected Effects of Radiation-Induced Cancers on Life Expectancy in Patients Undergoing CT Surveillance for Limited-Stage Hodgkin Lymphoma: A Markov ModelKathryn P Lowry, Ekin A Turan, Jonathan Eisenberg, et al.
Neuron|August 18, 2004
Protein kinase G type II is required for night-to-day progression of the mammalian circadian clockShelley A Tischkau, Jennifer W Mitchell, Laura A Pace, et al.
Cancer|June 22, 2010
Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphomaJeremy S Abramson, Matthew Hellmann, Jeffrey A Barnes, et al.
Hematological Oncology|June 30, 2018
Panobinostat in combination with rituximab in heavily pretreated diffuse large B-cell lymphoma: Results of a phase II studyJeffrey A Barnes, Robert Redd, David C Fisher, et al.
Science (New York, N.Y.)|October 18, 2003
Requirement of mammalian Timeless for circadian rhythmicityJessica W Barnes, Shelley A Tischkau, Jeffrey A Barnes, et al.
Leukemia & Lymphoma|January 8, 2013
Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 studyJeremy S Abramson, Ronald W Takvorian, David C Fisher, et al.
Leukemia & Lymphoma|June 6, 2013
Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory diseaseJacob D Soumerai, Matthew D Hellmann, Yang Feng, et al.
Blood|June 13, 2019
Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphomaJeremy S Abramson, Jon E Arnason, Ann S LaCasce, et al.
Haematologica|November 13, 2012
Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphomaJeffrey A Barnes, Eric Jacobsen, Yang Feng, et al.
Pageof 3